| Similar Articles |
|---|
 |
The Motley Fool
May 7, 2007
Mike Havrilla |
Advanced Life Makes Progress After positive data in an anthrax study, Advanced Life Sciences' potential antibiotic cethromycin has been granted FDA Orphan Drug status for this indication. Investors, take note.   |
The Motley Fool
November 30, 2009
Brian Orelli |
The FDA Moves the Goalposts The FDA sends a complete response letter to Theravance about its antibiotic Vibativ, which it's trying to get approved for treating patients with nosocomial pneumonia. |
The Motley Fool
May 30, 2008
Brian Orelli |
No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 31, 2007
Brian Lawler |
Lower Expectations for Theravance The FDA decides to debate Theravance's lead drug, Telavancin, leading to a drop in share price. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
February 28, 2008
Brian Lawler |
FDA's Mixed Signals for Theravance The FDA gives Theravance frustrating double messages about a lead drug. |
The Motley Fool
June 22, 2010
Dave Mock |
A Big Upgrade for DepoMed This bullish call comes from more than just one analyst. |
The Motley Fool
March 25, 2009
Brian Orelli |
Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
The Motley Fool
January 31, 2011
Brian Orelli |
Drug Approved! Now Who's Going to Launch It? Depomed gets pain-free news from the FDA. |
The Motley Fool
January 16, 2008
Brian Lawler |
Better Safe Than Sorry at Theravance Pharmaceutical company Theravance is raising cash in advance of an FDA hearing. Investors, take note. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
January 19, 2011
Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
The Motley Fool
February 18, 2010
Brian Orelli |
Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance. |
Chemistry World
September 25, 2013
Phillip Broadwith |
New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets. |
The Motley Fool
June 3, 2011
Frank Vinluan |
GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news. |
The Motley Fool
July 11, 2007
Brian Lawler |
Why Depomed Shares Were Dumped In a recent trial, a pain medication wasn't as effective as had been hoped. Investors, take note. |
The Motley Fool
October 6, 2004
W.D. Crotty |
2 IPOs Priced to Perfection These IPOs had grand welcomes: Steakhouse operator Texas Roadhouse... Biopharmaceutical Theravance... |
The Motley Fool
August 9, 2007
Brian Lawler |
Depomed Is Distressed Depomed announces its distressing second-quarter financial results, with failed phase 3 studies and under-performing drugs. |
The Motley Fool
April 30, 2007
Mike Havrilla |
ThermoGenesis Is Ready to Heat Up Shares of ThermoGenesis are currently trading at compelling levels that could produce nice gains if the company receives FDA approvals and subsequently ramps up the sales of its umbilical cord blood stem cell processing machines and ancillary products. |
The Motley Fool
August 21, 2008
Brian Orelli |
Johnson & Johnson Gets Rejected The FDA rejects Johnson & Johnson's bid to expand the label of its antibiotic. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
December 27, 2010
Brian Orelli |
FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
May 25, 2011
Brian Orelli |
Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
Chemistry World
May 6, 2014
Andy Extance |
WHO raises alarm on deadly bacteria The World Health Organization has warned antibiotic resistant bacteria could bring a nightmarish future, where seemingly trivial scrapes turn lethal, and currently routine operations become too risky to contemplate. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
March 26, 2008
Brian Lawler |
Take Two for Depomed The pharmaceutical starts another study for its proposed pain drug. The new study will double the size of patients enrolled and help reduce placebo effects. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
May 31, 2011
Brian Orelli |
Down! Up! Which Way Will Optimer Go Next? Long-term prospects look good. |
BusinessWeek
June 12, 2006
Catherine Arnst |
Going From The Lab To Limbo The FDA has been delaying decisions on applications, and drugmakers are fuming. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool
December 11, 2009
Brian Orelli |
Gilead Gets the Experts on Its Side An advisory committee says yes after the FDA said no. |
